Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder.

Responses to venlafaxine treatment in major depressive disorder were stratified by COMT genotypes (Val158Met, rs4680) in a randomized, double-blind, placebo-controlled clinical trial. Improvements in depression scores among subjects with Val/Val genotypes were larger than those in Met/Met genotypes, suggesting that venlafaxine may alter noradrenergic flux differentially according to COMT activity.

RCT Entities:   Population Interventions Outcomes